|
MechanismVMAT2 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date03 Apr 2017 |
安泰坦(氘丁苯那嗪)治疗成人迟发性运动障碍有效性及安全性的中国真实世界研究
[Translation] A real-world study in China on the efficacy and safety of Antaetan (deutetrabenazine) in the treatment of tardive dyskinesia in adults
评估安泰坦(氘丁苯那嗪)治疗中国成人迟发性运动障碍患者的安全性数据
[Translation] Evaluating the safety of Antaetan (deutetrabenazine) in the treatment of Chinese adult patients with tardive dyskinesia
一项评价单次给药12 mg安泰坦®片剂在健康中国受试者中的氘丁苯那嗪及其活性代谢物的药代动力学特征的开放性、单剂量研究
[Translation] An open-label, single-dose study evaluating the pharmacokinetic profile of deutetrabenazine and its active metabolite in healthy Chinese subjects after a single 12 mg dose of Antaetan® tablets
评价健康中国男性和女性受试者餐后单次口服12 mg TEV-50717片剂后TEV-50717(母体药物)及其活性氘代代谢物α-二氢丁苯那嗪(α-HTBZ)和β-二氢丁苯那嗪(β-HTBZ)(总和及单个成分)的药代动力学特征。
[Translation] To evaluate the pharmacokinetic profiles of TEV-50717 (parent drug) and its active deuterated metabolites α-dihydrotetrabenazine (α-HTBZ) and β-dihydrotetrabenazine (β-HTBZ) (total and individual components) after a single oral dose of 12 mg TEV-50717 tablets in healthy Chinese male and female subjects after a meal.
An Open-Label, Single Dose Trial to Characterize the Pharmacokinetics of Deutetrabenazine and its Active Metabolites in Healthy Chinese Participants After a Single Dose of a 12-mg AUSTEDO® Tablet
100 Clinical Results associated with Teva Medical Information Consulting (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Teva Medical Information Consulting (Shanghai) Co., Ltd.
100 Deals associated with Teva Medical Information Consulting (Shanghai) Co., Ltd.
100 Translational Medicine associated with Teva Medical Information Consulting (Shanghai) Co., Ltd.